Chargement des cours...

Prévisions

L'objectif de cours moyen des analystes est de 30,16 € (-3,64 %). La médiane est de 28,12 € (-10,16 %).

Acheter
  8
Conserver
  7
Vendre
  0

Discussions dans la communauté

Il n'y a pas encore de discussion sur cet actif.

Lancer une discussion

  • Double downgrade drives Trupanion stock sharply lower

    The stock of Trupanion fell about 6.4% in morning trading after Piper Sandler cut its rating from "Overweight" to "Neutral" and lowered the price target from $45 to $32. Piper Sandler cited declining puppy vet visits and more costly, aging COVID cohorts as headwinds for premium growth and underwriting margins. A simultaneous downgrade by Zacks intensified the sell-off, while the new price target, near the current share price, signals only limited short-term upside. » Plus sur de.investing.com


  • Trupanion beats Q2 earnings forecast and highlights outlook for 2026

    Trupanion reported Q2/2026 earnings of $0.16 per share, beating the $0.1133 forecast, on revenue up 11% to $392.9m. Adjusted operating income from subscriptions rose 24% and subscription revenue grew 14% to $276.7m, while the number of insured pets increased 5% to 1.125m. The stock rose 6.7% after hours; management confirmed a 2026 revenue range of $1.584–1.601bn and adjusted operating income of $176–184m. Risks remain higher customer acquisition costs, ongoing veterinary price inflation and execution risks for new product options. » Plus sur de.investing.com


  • Trupanion reaches 52-week low at $24.13

    Trupanion shares fell to a 52-week low of $24.13 after losing about 34% over the past year and roughly 40% in recent months. For Q4 2025 the company reported earnings per share of $0.13 (forecast $0.16) and revenue of $376.9 million (+12% year over year), slightly beating expectations. Analysts cut price targets (Cantor Fitzgerald 42→34 USD, Stifel 35→31 USD) citing growth and scaling concerns, while InvestingPro signaled possible undervaluation and upside; Trupanion also announced a research collaboration with the Human Animal Bond Research Institute. » Plus sur de.investing.com


  • Trupanion falls to 52-week low of $24.30

    Trupanion shares hit a new 52-week low at $24.30, down about 31.7% year-to-date; the six-month performance is down nearly 38%. The company reported Q4 2025 EPS of $0.13 (expectation $0.16) on revenue of $376.9 million (+12% YoY, forecast $375.21 million). Analysts cut price targets (Cantor Fitzgerald 42 → 34 USD, Stifel 35 → 31 USD), citing growth and scaling issues, while InvestingPro sees an undervaluation of around 38% and expects profitability this year. Trupanion also announced a partnership with the Human Animal Bond Research Institute to support studies on human-animal relationships. » Plus sur de.investing.com


  • Trupanion hits 52-week low after sharp share decline

    Trupanion shares closed at $24.49, marking a 52-week low after declines of 33.06% over the past year, 43% in six months and 31% year-to-date. Investors are worried about slowing growth and competitive pressure in the pet insurance industry, although a PEG of 0.19 suggests possible undervaluation. In Q4 2025, Trupanion missed the EPS expectation (0.13 vs. $0.16) while revenue rose 12% to $376.9 million; a partnership with the Human Animal Bond Research Institute was also announced. » Plus sur de.investing.com

En 2022, Trupanion a déjà versé 0,0078 € de dividendes. Le dernier versement a eu lieu en avril 2022.

Données financières de l'entreprise

Au dernier trimestre, Trupanion a réalisé un chiffre d'affaires de 358,08 M € et un bénéfice net de 8,19 M €
(EUR) septembre 2026
YoY
Chiffre d'affaires 358,08 M 14,52 %
Bénéfice brut 61,36 M 19,90 %
Bénéfice net 8,19 M 63,74 %
EBITDA 14,03 M 22,48 %

Données fondamentales

Indicateur Valeur
Capitalisation boursière
1,35 Md €
Nombre d'actions
43,27 M
Plus haut/bas sur 52 semaines
35,26 € - 19,20 €
Dividendes Non
Bêta
1,30
Ratio P/E
56,52
Ratio PEG
0,76
Ratio P/B
3,77
Ratio P/S
0,96

Profil de l'entreprise

Trupanion, Inc., ainsi que ses filiales, propose une assurance santé pour chats et chiens sur la base d'un abonnement mensuel aux États-Unis, au Canada, à Porto Rico et en Australie. La société exerce son activité à travers deux segments, Subscription Business et Other Business. Elle s'adresse aux propriétaires d'animaux de compagnie et aux vétérinaires. La société était auparavant connue sous le nom de Vetinsurance International, Inc. et a changé son nom en Trupanion, Inc. en 2013. La société a été fondée en 2000 et son siège social se situe à Seattle, dans l'État de Washington.

Nom
Trupanion
PDG
Margaret Rosemary Maria Tooth
Siège social Seattle, wa
États-Unis
Site web
Secteur
Finance
Industrie
Assurance
Introduction en bourse
18/07/2014
Employés 1 121

Symboles boursiers

Bourse Symbole
NASDAQ
TRUP
London Stock Exchange
0LH0.L
Frankfurt
TPW.F
Düsseldorf
TPW.DU
London
0LH0.L
SIX
TPW.SW
München
TPW.MU
🍪

Parqet  utilise des cookies. En savoir plus